Synoptical view

    Truffle investment
    € 9M
    Stock
    Deinove is listed on EURONEXT GROWTH since april 2010
deinove_bacteries_4.jpg

Management team

emmanuel_petiot.jpg

Emmanuel Petiot

CEO

julien_coste.jpg

Julien Coste

CFO

Board of Directors

charles_woler.jpg

Dr.Charles Woler

President

anne_abriat_hemmendinger.jpg

Anne Abriat-Hemmendinger

Administrateur indépendant

In summary

Deinove has developed a unique and exhaustive expertise in the field of rare bacteria that it knows how to decipher, cultivate, optimize to reveal their unsuspected possibilities and thus make them produce on an industrial scale biosourced molecules with activities of interest. To this end, since its creation, Deinove has built up and documented an unrivalled reserve of biological diversity that it exploits thanks to a technological platform that is unique in Europe. The company is developing in two areas of activity:

  • ANTIBIOTICS, new generation anti-infectives: Phase II clinical trial of a first candidate antibiotic. The Company is also pursuing systematic exploration of biodiversity to supply its portfolio with new leads, notably through partnerships with Naicons and bioMérieux (AGIR program supported by Bpifrance).
  • BIOACTIVES, active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: Deinove already markets a first innovative active ingredient, a second in partnership with Greentech, while two others are in development with Oléos (Hallstar Group). She also runs an animal nutrition program with the April Group.

In video

They talk about it

It is urgent to innovate to discover the antibiotics of tomorrow. All over the world, the effectiveness of antibiotics is decreasing; infections that we thought had disappeared forever are resurfacing, thanks to pathogenic bacteria that no longer fear existing therapies.

Media

"Deinove has developed a unique and exhaustive expertise in the field of rare bacteria that it knows how to decipher, cultivate, optimize to reveal their unsuspected possibilities and thus make them produce on an industrial scale biosourced molecules with activities of interest. To this end, since its creation, Deinove has built up and documented an unrivalled reserve of biological diversity that it exploits thanks to a technological platform that is unique in Europe. The company is developing in two areas of activity:

  • ANTIBIOTICS, new generation anti-infectives: Phase II clinical trial of a first candidate antibiotic. The Company is also pursuing systematic exploration of biodiversity to supply its portfolio with new leads, notably through partnerships with Naicons and bioMérieux (AGIR program supported by Bpifrance).
  • BIOACTIVES, active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: Deinove already markets a first innovative active ingredient, a second in partnership with Greentech, while two others are in development with Oléos (Hallstar Group). She also runs an animal nutrition program with the April Group."
rohde_und_schwarz_cybersecurity_web_application_firewall_slider.jpg

Next start-up

DenyAll